VanEck Biotech ETF Stock Forecast, Price & News

Wall Street analysts have given VanEck Biotech ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VanEck Biotech ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

VanEck Biotech ETF pays an annual dividend of $0.61 per share and currently has a dividend yield of 0.28%.
View VanEck Biotech ETF's dividend history.

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Biotech ETF investors own include Abiomed (ABMD), Catalent (CTLT), Hologic (HOLX), Merck & Co., Inc. (MRK), Net Element (NETE), Novavax (NVAX), Quanterix (QTRX), Tesla (TSLA), ARCA biopharma (ABIO) and AbbVie (ABBV).

VanEck Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "BBH."

Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BBH stock can currently be purchased for approximately $216.34.

VanEck Biotech ETF has a market capitalization of $621.33 million.